epocrates logo
epocrates logo
epocrates logo
  • 0

Government Health Agency Alert

FDA

Risk of severe tissue injury spurs FDA warning regarding injectable promethazine

January 5, 2024

card-image

FDA is alerting clinicians of labeling updates intended to further reduce risk of severe chemical irritation and tissue damage from IV administration of promethazine HCl injection. The agency recommends deep IM administration of the drug instead of IV. If IM injection isn’t possible, promethazine HCl can be given IV only after dilution, as recommended, through an IV catheter inserted in a large vein, preferably a central venous catheter. The drug shouldn’t be mixed with other drugs or diluted with solutions other than 0.9% NaCl and is contraindicated for IV use at concentrations >1 mg/mL.

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information